In view of this, the increased functional α7 nAChR due to lower CHRFAM7A expression is able to sustain enhanced Aβ1–42 internalization and neuronal vulnerability, and therapies with α7 antagonists may be more effective in these AD patients. The gene discussed is IGKV2D-24; the disease is Alzheimer disease.